GLUCOSE & FDG IMAGING IN CANCER

葡萄糖

• 批准号: 6119772
• 负责人: Michael M. Graham
• 金额: --
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-16 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6119772
• 关键词: Mammalia; bioengineering /biomedical engineering; biomedical resource; human tissue; model design /development; technology /technique

F-18 fluorodeoxyglucose (FDG) used with positron emission tomography (PET) has been shown to be very effective for detecting malignant tumors in vivo. It is assumed the increased uptake seen in tumors is due to increased glycolysis, i.e. increased metabolism of glucose to lactate. However, an alternative possibility, based on direct measurements of uptake of glucose and FDG by tumors is that tumors have an increased affinity for FDG. The term "lumped constant" is the ratio of uptake of FDG to that of glucose. It seems to be elevated in tumors. The overall goal of this project is to understand the mechanism for the relative increased uptake of FDG by tumors and to take advantage of this difference by optimizing the analysis methodology and the imaging protocols.

F-18氟脱氧葡萄糖（FDG）与正电子发射 断层扫描（PET）已被证明对检测非常有效 体内恶性肿瘤。 假设在 肿瘤是由于糖酵解增加所致，即增加的代谢 葡萄糖至乳酸。 但是，基于 直接测量肿瘤对葡萄糖和FDG的摄取是 肿瘤对FDG的亲和力增加。 术语“集结常数” 是FDG摄取与葡萄糖的摄取之比。 似乎是 肿瘤升高。 该项目的总体目标是了解 肿瘤和 通过优化分析来利用这种差异 方法论和成像协议。